• If you are wondering whether Cencora at about US$270.78 is starting to look attractive or stretched, the key question is what you are really paying for its future cash flows and business quality.
• The stock is up 1.7% over the last week, even though it is down 12.1% over the last month, 20.1% year to date and 7.0% over the last year, while the 3 year and 5 year returns stand at 67.4% and 149.4% respectively.
• Recent news around Cencora has focused on its role as a major healthcare distributor and on how market sentiment reacts when expectations for the broader sector shift. Along with coverage that highlights its scale within the US healthcare system, this context helps explain why the share price can move sharply as investors reassess risk and long term growth assumptions.
• Cencora currently records a valuation score of 6/6. The next sections will break down what that means using approaches like discounted cash flow and multiples, and will finish with a perspective that can help you interpret valuation in a more complete way.

Approach 1: Cencora Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today’s value using a required return.

For Cencora, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows reported and projected in $. The latest twelve month free cash flow is about $1.66b. Analyst and extrapolated estimates suggest annual free cash flow reaching about $4.53b in 2035, with interim projections such as $3.12b in 2026 and $4.38b in 2030. These projected cash flows are then discounted to reflect today’s value.

When Simply Wall St adds up all those discounted cash flows, the estimated intrinsic value comes out at about $486.69 per share. Against a recent share price of roughly $270.78, the DCF indicates an implied 44.4% discount. On this model, the stock appears undervalued rather than fully priced.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 44.4%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Cencora Price vs Earnings

For profitable companies like Cencora, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It links directly to the core driver of equity value, the ability to generate earnings for shareholders.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risks. Higher expected growth or lower perceived risk can justify a higher P/E, while slower expected growth or higher risk tends to anchor the P/E lower.

Cencora currently trades on a P/E of about 20.67x. That compares with a Healthcare industry average P/E of about 24.13x and a peer average of roughly 25.65x. Simply Wall St also calculates a proprietary “Fair Ratio” of 25.55x for Cencora, which is the P/E level suggested by factors such as its earnings profile, industry, profit margins, market cap and risk characteristics. This Fair Ratio can be more informative than a simple comparison with peers or industry averages, because it ties the valuation back to company specific fundamentals rather than broad groupings.

The current P/E of 20.67x is below the Fair Ratio of 25.55x, which indicates that the stock is trading at a discount on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Cencora Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Cencora into a clear story that links what you think about its business, future revenue, earnings and margins to a financial forecast and a Fair Value that you can compare with the current share price. This can help you decide whether it looks appealing or expensive, all within an easy to use Community page. Narratives refresh automatically when new news or earnings arrive, and one investor might lean toward the more cautious Fair Value around US$280, while another aligns with the higher consensus view near US$373, giving you a transparent range of perspectives to choose from.

Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.